Clinical Trial Update: Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations [Phase 3]

View source ↗

Summary

Phase III trial comparing Elortinib to Gefitinib in adults with advanced non-small cell lung cancer harboring EGFR exon 19 or 21 mutations has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Elortinib
• Gefitinib (Gefitinib)

Snippet

Sponsor: Chinese Society of Lung Cancer | Conditions: Thoracic Neoplasms | Phase 3 | Status: COMPLETED